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The treatment of Parkinson’s disease (PD) using stem cells has long been the focus of many researchers,
but the ideal therapeutic strategy has not yet been developed. The consistency and high reliability of the
experimental results conﬁrmed by animal models are considered to be a critical factor in the stability of
stem cell transplantation for PD. Therefore, the aim of this study was to investigate the preventive and
therapeutic potential of human adipose-derived stem cells (hASC) for PD and was to identify the related
factors to this therapeutic effect. The hASC were intravenously injected into the tail vein of a PD mouse
model induced by 6-hydroxydopamine. Consequently, the behavioral performances were signiﬁcantly
improved at 3 weeks after the injection of hASC. Additionally, dopaminergic neurons were rescued, the
number of structure-modiﬁed mitochondria was decreased, and mitochondrial complex I activity was
restored in the brains of the hASC-injected PD mouse model. Overall, this study underscores that
intravenously transplanted hASC may have therapeutic potential for PD by recovering mitochondrial
functions.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disease. The onset rate is estimated to be about 1%e2% of
individuals aged >60 years and >3% of the number aged >75 years
(Gasser, 2009; Pankratz and Foroud, 2007). Aging, genetic and
environmental factors are jointly involved in the development of
PD, though the exact mechanismwas poorly understood. Especially,
many epidemiological studies have reported that aging is the
greatest risk factor for PD (Bennett et al., 1996; Morens et al., 1996;
Tanner and Goldman,1996). The signs and symptoms of PD are slownstitute (KBRI), Daegu, 701-
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Inc. This is an open access article umovement, rigidity, and tremor because of the loss of dopaminergic
neurons in the substantia nigra (SN) that project to the striatum
(Murrell et al., 2008). The progressive degeneration and loss of
dopaminergic neurons in the SN are accompanied by the formation
of intraneuronal inclusions, called “Lewy body,” that are primarily
composed of a-synuclein (Spillantini et al., 1997). However,
no treatment has yet been developed because their interplay is still
unclear. Lately, PD treatments have tried to compensate for the loss
of striatal dopamine by administering its precursor L-DOPA and/or
dopamine D2 receptor agonists (Collier et al., 2011; Dragicevic et al.,
2014; Gazewood et al., 2013; Olanow and Schapira, 2013).
Recently, stem cell therapy for PD has been in the spotlight.
The ideal transplantable cell should be easily accessible, have a
high proliferation capacity in vitro, and have the ability to undergo
differentiation into multiple cell lineages such as astrocytes, oli-
godendrocytes, and neuronal cells. In recent studies, human
adipose-derived stem cell (hASC), a type of mesenchymal stem cell
(MSC) isolated from adipose tissue, are well known for their
pluripotent ability to differentiate into neuron-like cellsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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niﬁcant advantages, such as the lack of immune rejection re-
sponses, tumorigenesis, and ethical problems (Tomita et al., 2013;
Zuk et al., 2002). Moreover, ASCs have already been used for
some clinical applications (Traktuev et al., 2008). Unlike stem cells
derived from other sources and induced pluripotent stem cells
(Amariglio et al., 2009; Bjorklund et al., 2002; Brederlau et al.,
2006; Duinsbergen et al., 2009), MSCs show a low probability of
being tumorigenic, and a recent phase I study demonstrated
the safety of MSC transplantation into PD patients
(Glavaski-Joksimovic and Bohn, 2013; Venkataramana et al., 2010).
Additionally, in our previous study, we found using an in vivo
imaging technique that intravenously transplanted hASC could
pass through the blood-brain barrier and migrate into the injuries
of the brain (Chang et al., 2014; Kim et al., 2012). For these reasons,
hASC may be the optimal stem cells for clinical therapies.
In many studies, it has been previously described that the struc-
tural and functional alterations ofmitochondriawere associatedwith
neurodegenerative diseases including PD. The genes related to PD,
such as a-synuclein, parkin, DJ-1, and PINK1, are directly or indirectly
involved with mitochondrial functions (Shim et al., 2011). Mito-
chondria supply adenosine triphosphate to the cell through oxidative
phosphorylation, synthesize key molecules, and buffer calcium gra-
dients (Frazier et al., 2006). Therefore,mitochondrial health is closely
associated with the metabolic component. Aging and energy-
dependent disturbances involve mitochondrial defects (Wang et al.,
2013b). In particular, impaired function of mitochondria leads to
increased oxidative stress or reactive oxygen species, and both have a
signiﬁcant pathogenic role in the selective loss of dopaminergic
neurons in human patients and in PD mouse models (Dexter et al.,
1989; Moon et al., 2013; Sriram et al., 1997).
Traditionally, the experimental models for PD have been created
in rodents and primates via the delivery of neurotoxins, such as
6-hydroxydopamine (6-OHDA) (Stott and Barker, 2014). It has been
reported that 6-OHDA is a dopamine analog that speciﬁcally in-
duces dopaminergic neuronal cell death via either uncoupling
mitochondrial oxidative phosphorylation, resulting in energy
deprivation or alternatively through its ability to produce hydrogen
peroxide, hydroxyl, and superoxide radicals (Soto-Otero et al.,
2008; Wang et al., 2013b). 6-OHDA is also known to inhibit com-
plexes I and IV of the mitochondrial respiratory chain in the SN
(Ben-Shachar et al., 1995; Glinka and Youdim, 1995; Glinka et al.,
1996; Mizuno et al., 1989).
In the present study, we focused on the applicability of hASC by a
convenient and safe intravenous injection and the relevance of hASC
tomitochondrial functions in a PDmousemodel induced by 6-OHDA
for the ﬁrst time. We investigated whether hASC injection could
rescue the behavioral deﬁcits in the PD mouse model using the
apomorphine-induced rotation test and the rotarodperformance test.
Toconﬁrmaneuropathological difference,weevaluatedthechange in
the numbers of tyrosine hydroxylase (TH)-positive neurons in hASC-
injected PD mice compared with sham control PD mice. To assess
whether injected hASC rescued alterations in the dopamine level in
the striatum, we performed positron emission tomography (PET)
imaging analysiswith [11C]raclopride, an antagonist of DA-D2R, in the
PD mouse model injected with hASC or saline. Additionally, we
focused on changes in the mitochondrial structure and complex I
activity in the experimental PD model.
2. Experimental procedures
2.1. Materials
hASCs (RNL-Bio_SM081201 P3), male C57BL6 mice, desipra-
mine, apomorphine, 6-OHDA (Sigma Aldrich Korea, Kyounggi-do,Korea), 25% glutaraldehyde (Electron Microscopy Sciences,
PA, USA), Dako EnVisionþ systemehorseradish peroxidaseela-
beled polymer (Dako Korea, Seoul, Korea), DABþ substrate
chromogen (Dako Korea), anti-TH antibody (Santa Cruz
Biotechnology, CA, USA), and the complex I enzyme activity
microplate assay kit (Abcam, Cambridge, UK) were used in the
experiments.
2.2. Method
2.2.1. PD mouse model preparation and behavioral testing
Seven-week-old male C57BL/6N mice weighing 20e25 g were
housed in a speciﬁc pathogen-free room, automatically main-
tained on a 12-hour light-dark cycle at 25 C and proper hu-
midity, and were given food and water ad libitum. Desipramine
(25 mg/kg, Sigma, St. Louis, MO, USA) was injected intraperito-
neally (ip) to block norepinephrine reuptake 1 hour before 6-
OHDA injection. The animals were anesthetized with Rompun
and Zoletil (1 mg/g, ip) and injected with 10 mg of 6-OHDA (4 mg/
mL containing 0.2 mg/mL L-ascorbic acid) or the same volume of
saline for the PD model or control, respectively. 6-OHDA or saline
was injected unilaterally into the SN (A/P ¼ 3.2, M/L ¼ 1.5, D/
V ¼ 4.6) with a ﬂat skull position (coordinates in mm, with
anterior-posterior and lateral coordinates measured from
bregma, and ventral from dura) using a Kopf stereotaxic frame
(Kopf Instruments, Tujunga, CA, USA). The injections were made
at a rate of 0.5 mL/min using a 25-gauge Hamilton syringe
(Hamilton Company, NV, USA). The in vivo experimental protocol
that followed is shown in Fig. 1A. After the surgery, each mouse
was kept in an individual cage.
Two weeks after the 6-OHDA injection, motor coordination, and
fatigue resistance were tested using the accelerating rotarod and
apomorphine-induced rotation tests for the measurement of
baseline behavior (n ¼ 10 per group). The control mouse and PD
mouse induced by saline or 6-OHDA, respectively, was selected by
the baseline behavior testing and distributed to each group. The
injection of hASC (1 106 cells) was conducted twice at an interval
of 2 weeks, and the behavioral performances were measured at
3 weeks after the ﬁnal injection of hASC via the rotation and
accelerating rotarod tests. For the rotation test, mice were habitu-
ated in the basket for 10minutes. After subcutaneous injectionwith
apomorphine (0.05 mg/kg), the behavior of the mouse was tracked
and the number of right and left rotations and the net number of
rotations for 30 minutes were analyzed by an EthoVision video
tracking system. For the rotarod test, mice were conditioned at a
speed of 8 rpm for 5 minutes and at a speed of 12 rpm for 5 minutes
at an interval of 1 hour. One day after the training, the motor
performance was tested at an accelerated speed from 2 rpm to
20 rpm for 10 minutes. The time schedule of the experimental
procedure is shown in Fig. 1.
2.2.2. Micro-positron emission tomography
The PET study with [11C]raclopride was performed 4e5 weeks
after the 2nd adipose-derived stem cells treatment (n ¼ 4 per
group). Anesthesia was induced and maintained with passive
1.5% isoﬂurane at an oxygen level of 1.5 L/min with vacuum.
Each mouse was positioned on a bed with its brain centered in
the gantry. The PET scan was performed using a Focus 120 Micro
PET system (Concorde Microsystems, Knoxville, USA). Dynamic
scans were performed for 90 minutes immediately after a [11C]
raclopride injection (18.50e24.64 MBq, 200 mL) via the tail vein.
The acquisition of data was reconstructed with a 2D-ﬁltered
back-projection algorithm (microPET Manager, Siemens Medical
Solutions, Knoxville, USA). The dynamic frame was composed of
32 frames: 1  60 seconds, 6  20 seconds, 2  30 seconds, 5 
Fig. 1. The motor performances were improved in hASC-transplanted PD mice. (A) 6-OHDA was injected into the SN of 6-week-old male mice and the baseline behavior tests were
performed at 2 weeks after the drug injection for the selection of the PD mouse model. hASC were transplanted twice at 3 weeks and 5 weeks after the 6-OHDA injection. Behavioral
assessments via the rotarod and rotation tests were performed at 3 weeks after the second injection of hASC. positron emission tomography images were obtained at 5 weeks after
the second injection of hASC, and the mice were sacriﬁced next week. (B) The 6-OHDA was stereotaxically injected into the SN (AP, 3.2 mm; ML, 1.5 mm; DV, 4.6 mm). (C) The
number of rotation induced by apomorphine was increased in PD mice and signiﬁcantly decreased in the hASC-injected group. (Average number of rotation, saline, 3  1; saline
and/or hASC, 2  1; 6-OHDA, 195  21; 6-OHDA and/or hASC, 123  14) ***p < 0.001; **p < 0.01 by 1-way analysis of variance, Tukey’s multiple comparisons test. Abbreviations:
hASC, human adipose-derived stem cells; IHC, immunohistochemistry; 6-OHDA, 6-hydroxydopamine; PET, positron emission tomography.
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onds. For the quantitative analysis, the reconstructed PET images
were analyzed with PMOD software (PMOD Technologies Ltd,
Zurich, Switzerland). The region of interest was set up as the left
and right striatum. The binding potential was measured in each
region of interest.
2.2.3. Immunohistochemistry
Themicewere anesthetizedwith Rompun and Zoletil (1 mg/g, ip)
and transcardially perfused by saline with heparin after the
completion of the behavioral tests. All the hemispheres were ﬁxed
overnight in 4% paraformaldehyde at 4 C and embedded with
parafﬁn. Coronal sections (4 mm) of parafﬁn-embedded hemi-
spheres were cut through the entire SN using a microtome (Thermo
Electron Corporation, OH, USA).
The brain slides were placed in a 55 C oven for 10 minutes to
melt the parafﬁn, rinsed in xylene for deparafﬁnization, and
dehydrated using a descending ethanol series. The sections were
retrieved by 0.01-M citric acid (pH 6.0) for 10 minutes at 60 C and
blocked with 0.5% triton X-100% and 2% normal serum in Tris-
buffered saline. The sections were incubated in primary antibody
(TH; 1:100) overnight at 4 C and were incubated with Dako
EnVisionþ systemehorseradish peroxidaseelabeled polymer for
30 minutes. After washing in Tris-buffered saline, the tissue slides
were incubated with liquid DABþ substrate chromogen (Dako) for
10e30 minutes at room temperature. The sections were rinsed
gently with distilled water and coverslipped with histomount
(Invitrogen) (Kim et al., 2014). Each experiment was repeated
3 times (n ¼ 3 per group).2.2.4. Transmission electron microscopy
For the transmission electron microscope (TEM) observations,
the mouse brains were isolated and ﬁxed with 2.5 % glutaraldehyde
in 0.1-M phosphate buffer (pH 7.4). The SN region was isolated,
sufﬁciently ﬁxed and cut into 1  1  1 mm cubes; a ﬁxation so-
lution was used to prevent the tissue from drying. Then, the tissue
cubes were washed in cacodylate buffer, postﬁxed with 1% osmium
tetroxideephosphate-buffered saline (PBS) solution for 1 hour,
dehydrated in a graded series of ethanol, inﬁltrated with propylene
oxide, and embedded in Epon (Xu et al., 2012). Ultrathin sections
were prepared and counterstained with 4% uranyl acetate and lead
citrate (Shirpoor et al., 2009). TEM imageswere then obtained using
a JEOL TEM (JEM-1400; Seoul National University Hospital Medical
Research Institute, Seoul, Korea) at an accelerating voltage of 80 keV
(Oh et al., 2010). The numbers of total and damaged mitochondria
were counted in 2e5 frames per cell in the 5 cells for each brain
sample (n ¼ 3 per group).
2.2.5. Mitochondrial complex I activity assay
The brain samples were homogenized with PBS containing a
protease inhibitor cocktail. The proteins were extracted by adding
detergent and centrifuging at 12,000g for 20 minutes. All samples
were diluted to a suitable concentration in the incubation solution.
The prepared samples were added into the microplate and
incubated for 3 hours at room temperature. Afterward, the wells
were emptied by turning the plate over and rinsed twice with
buffer. The assay solutionwas added into the emptied wells and any
bubbles were removed as rapidly as possible. The plate was placed
in the reader, and kinetic measurements were recorded at 450 nm
Fig. 2. The striatal dopamine transmission was restored and loss of dopaminergic neurons was decreased by the transplantation of hASC. The binding of dopamine with dopamine
D2 receptors was measured in the striatum by the representative summed positron emission tomography (PET) images at 5 weeks after the second injection of hASC. (A) The images
of the striatum of the 6-OHDA- or 6-OHDA and/or ASC-injected mouse were acquired by PET using [11C]raclopride. The binding of [11C]raclopride to dopamine D2 receptors was
decreased in the hASC-injected PD mouse model compared to the PD mouse (left; normal, right; lesion). (B) A numerical value of binding potential is shown in a graph. The graph
indicates the difference of value between the normal side and the lesioned side of the 6-OHDA- or 6-OHDA and/or ASC-injected mouse. There was no signiﬁcant difference in the
hASC-injected PD mouse. (C) The brain slices were immunostained with an anti-TH antibody. TH-positive dopaminergic neurons were visualized by DAB staining for light
microscope observation. Dopaminergic neuronal cell death in the SN was sharply increased after the injection of 6-OHDA, and the dopaminergic neurons recovered with the hASC
transplantation. (D) Dopaminergic neurons were counted and are shown by a graph. (Average number of TH-positive cells, saline, 105  0.86; saline and/or hASC, 134  1.84;
6-OHDA, 3.33  0.62; 6-OHDA and/or hASC, 42  1.69) ***p < 0.001; *p < 0.05 by 1-way analysis of variance, Fisher’s lysergic acid diethylamide test. Abbreviations: hASC, human
adipose-derived stem cells; 6-OHDA, 6-hydroxydopamine; SN, substantia nigra; TH, tyrosine hydroxylase.
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repeated 3 times (n ¼ 3 per group).
2.3. Ethics statement
The animals used in this experiment were handled in accor-
dance with the Guidelines for Animal Experimentation. This study
was approved by the Ethics Committee of Seoul National University
Institutional Animal Care and Use (SNU IACUC; approval ID;
SNU100819-1e2).
2.4. Statistical analysis
The relationship among the groups was determined by Student t
test and 1-way analysis of variance using GraphPad Prism 6
(GraphPad software, CA, USA). p-Values < 0.05 were considered
statistically signiﬁcant (*p < 0.05; **p < 0.01; ***p < 0.001).
3. Results
3.1. Intravenously transplanted hASC improved motor performances
in the 6-OHDA-induced PD mouse model
To determine the effects of hASC transplantation in PD, hASC
was intravenously transplanted into the tail-vein of the sham
control or 6-OHDA-induced PD mice. Because 6-OHDA, as a speciﬁc
catecholaminergic neurotoxin, is not able to cross the blood-brain
barrier, stereotaxical injection of 6-OHDA into the SN is necessary
to cause the nigrostriatal damage.Next, the functional impairments were monitored by
rating animal rotations induced by apomorphine and evaluating
maximal motor performance using the accelerating rotarod test
(Fig. 1). Because our PD mouse model had unilateral nigrostriatal
damage in the right hemisphere, the rotational behavior by
apomorphine, a dopamine receptor agonist, was used to inves-
tigate nigrostriatal function. 6-OHDA-injected mice spontane-
ously exhibited severe full-body contralateral rotations after a
single subcutaneous administration of apomorphine (Fig. 1C). In
contrast, the hASC-injected PD mice showed signiﬁcantly
decreased net rotations (average number of rotation, saline, 3
 1; saline and/or hASC, 2  1; 6-OHDA, 195  21; 6-OHDA/
hASC, 123  14).
The accelerating rotarod result showed that the motor coor-
dination and fatigue resistance were improved in the hASC-
injected PD group compared with the PD group (Supplementary
Fig. 1). No difference was observed between the saline-injected
and saline and/or hASC-injected groups (Supplementary Fig. 1).
PD mice dropped quickly from the rotarod with less movement,
but the hASC-injected PD mice endured for more time and had
better movement on the rotarod than the PD mice
(Supplementary Fig. 1) (Average time, saline, 481  23; saline and/
or hASC, 511  22; 6-OHDA, 201  14 seconds; 6-OHDA and/or
hASC, 257  25 seconds). Behavioral tests were performed at
3 weeks after the intravenous injection of hASC or saline and were
measured by the apomorphine rotation and accelerating rotarod
tests.
Our data clearly show that the intravenously engrafted hASC
alleviated some of the motor system dysfunction.
Fig. 3. Damaged mitochondria were rescued by the transplantation of hASC in PD mice. Mitochondrial images were obtained by transmission electron microscope. (A) Damaged and
undamaged mitochondria were counted on the 15 ﬁelds of 5 cells in the substantia nigra isolated from each brain sample. The ruptured and impaired mitochondria were increased
in 6-OHDA-injected mice and decreased by hASC injection. The enlarged images of the areas marked with an asterisk are indicated on the right. (B) The percentage of normal or
damaged mitochondria is represented by a graph. (Normal mitochondria, saline, 91.66  1.13; saline and/or hASC, 95.46  0.71; 6-OHDA, 70.50  3.18%; 6-OHDA and/or hASC, 93.06
 0.85%) ***p < 0.001 by 1-way analysis of variance, Tukey’s multiple comparisons test. Abbreviations: hASC, human adipose-derived stem cells; 6-OHDA, 6-hydroxydopamine.
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neuronal cell death in the 6-OHDA-induced PD mouse model
To assess dopaminergic neuropathology, a PET imaging
analysis was performed in 6-OHDA-injected or 6-OHDA and/or
hASC-injected mice using raclopride (S-()-3,5-dichloro-N-[(ethyl-
2-pyrrolidinyl)]methyl-2-hydroxy-6-methoxybenzamide) as a PET
tracer. Raclopride, a dopamine D2 receptor antagonist, was radio-
labeled with 11C ([11C]raclopride) for imaging dopamine D2
receptors in the striatum and to assess the degree of dopamine
binding. The destruction of dopaminergic neurons in the SN by
6-OHDA leads to the consecutive depletion of dopamine in the
striatum. Consequently, PD mice showed a marked increase in [11C]
raclopride binding to dopamine D2 receptors (Fig. 2A, left). In
contrast, hASC-injected PD mice showed decreased binding of [11C]
raclopride with the dopamine D2 receptor according to the recovery
of dopamine in the striatum (Fig. 2A, right). A numerical value of
binding potential is shown in Fig. 2B. Striatal [11C]raclopride binding
potential in the PDmousewas signiﬁcantly different between the left
striatum (1.05  0.06) and right striatum (1.56  0.14). In contrast,
the binding potential in the hASC-injected PD mouse exhibited no
signiﬁcant difference between the left striatum (1.16  0.20) and
right striatum (1.50  0.27). This result indicates that the trans-
plantation of hASC decreased difference in the binding between the
left striatum (intact) and right striatum (lesioned) value.
We also examined the neuroprotective effect of hASC trans-
plantation on 6-OHDA-induced dopaminergic neuronal cell death.
Brain sections from each group were prepared from a parafﬁn block
and immunostained with an anti-TH antibody. TH-positive dopa-
minergic neurons were severely decreased by the injection of
6-OHDA and signiﬁcantly recovered with hASC transplantation
(Fig. 2C). When the number of TH-positive dopaminergic neurons
in the SN for each group was counted and quantiﬁed, a signiﬁcant
difference was found between the 6-OHDA and 6-OHDA and hASC
group (Average number of TH positive cells, saline, 105  0.86;saline and/or hASC, 134  1.84; 6-OHDA, 3.33  0.62; 6-OHDA and/
or hASC, 42  1.69; p < 0.05; Fig. 2D).
Based on these ﬁndings, we concluded that hASC
transplantation rescued the dopaminergic neurons in the SN and
functionally improved the level of dopamine transmission.3.3. Ruptured and damaged mitochondria were decreased by hASC
injection in the region of the SN in the PD mouse model
Many studies have reported structural and functional modiﬁ-
cations of the mitochondria in various neurodegenerative diseases,
including PD, Alzheimer’s disease and amyotrophic lateral sclerosis
(Lin and Beal, 2006). Therefore, we focused on the characteristics of
the mitochondria in the PD mouse model with or without hASC
transplantation. To investigate whether hASC are responsible for
the recovery of damaged mitochondria in the region of the SN, we
observed the level of structural degeneration of mitochondria using
a TEM. Abnormal structural features, such as the ruptured mem-
brane and collapsed cristae, were observed in the damaged mito-
chondria in the SN of the 6-OHDA-induced PD mice (Fig. 3A). The
number of damaged mitochondria was signiﬁcantly increased in
the 6-OHDA-induced PD group compared with the control group
(Fig. 3A and B). This morphological damage was decreased by the
transplantation of hASC (Fig. 3A). The number of undamaged
and damaged mitochondria was counted. Each area denoted
marked with an asterisk in the 4 ﬁgures was enlarged and is shown
on the right of Fig. 3A. The percent of undamaged (Fig. 3B top) or
damaged (Fig. 3B bottom) mitochondria was calculated and is
represented by the bar graphs. In the 6-OHDA and hASC group, the
population of damaged mitochondria was signiﬁcantly decreased
(22.56%, p < 0.001), compared to the 6-OHDA group (Fig. 3B).
(Undamaged mitochondria, saline, 91.66  1.13; saline and/or hASC,
95.46  0.71; 6-OHDA, 70.50  3.18%; 6-OHDA and/or hASC,
93.06  0.85%).
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SN of hASC-injected PD mouse model
To conﬁrm the effect of hASC in the function of mitochondria, we
performed a mitochondrial enzyme activity assay related to the
mitochondrial respiratory chain. The SN region was isolated in
4 mouse brains per group and homogenized with PBS. Mitochon-
drial complex I was immunocaptured from tissue lysate within the
wells of the microplate, and the activity was determined by
the oxidation of nicotinamide adenine dinucleotide to NADþ and
the reduction of a dye that resulted in the increase in absorbance at
450 nm.
Mitochondrial complex I, a nicotinamide adenine dinucleoti-
deequinone oxidoreductase, is the ﬁrst enzyme in the mitochon-
drial respiratory chain and has been highlighted as a factor in the
etiology of PD (Marella et al., 2009). Decreased complex I activity
ultimately leads to dopaminergic neuronal cell death, producing
reactive oxygen species and a decreased energy supply
(Abou-Sleiman et al., 2006; Marella et al., 2009). In our study,
mitochondrial complex I activity was decreased by 6-OHDA, which
is known to inhibit mitochondrial complex I. During the 30-minute
reaction, the maximum optical density at 450 nm is shown in
Fig. 4A. The activity of this enzyme was restored by the trans-
plantation of hASC. PD group showed a signiﬁcant decrease in
mitochondrial complex I activity (27.78%, p < 0.001), and hASC
injection restored the activity to control levels (21.72%, p < 0.01)
(Fig. 4B); saline, 100  3.05%; saline and/or hASC, 101.94  4.24%;
6-OHDA, 72.21  2.94%; 6-OHDA and/or hASC, 93.94  3.20%.
4. Discussion
Chronic neurodegenerative diseases, including PD, Alzheimer’s
disease, and Huntington disease could be caused by aging, which
are characterized by gradually progressive and selective neuronal
loss. This pathological characteristic results in marked dysfunction
of the neural system with a concomitant lack of the neurotrans-
mitter. In particular, PD involves dopaminergic neuronal loss and
the depletion of dopamine. Therefore, the goal of cell-based ther-
apies for PD is the replacement of dopaminergic neurons in the SN
or the protection of these neurons from further loss (Joyce et al.,
2010). Recent studies have been showed that MSCs displayedneuroprotective effect through autophagy modulation (Park et al.,
2014), and dopaminergic carotid body grafts could protect SN
dopaminergic neuronal degeneration in an MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine)-induced PD mouse model
(Munoz-Manchado et al., 2013).
The ideal cell sources for the treatment of neurodegenerative
disease are easily obtained in abundant quantities, can differentiate
into multiple cell lineages, and can have high-proliferation ability
in vitro. The hASC used in this study can be separated easily from
adipose tissue and have a multipotent ability to differentiate into
neural cells (Zuk et al., 2002). Several studies recently reported that
ASCs had multilineage differentiation potential and could differ-
entiate into neuron-like cells in the neurogenic induction medium,
displaying morphological changes and the expression of neuronal
markers, such as b-tubulin III (Tuj-1) and glial ﬁbrillary acidic
protein (Wang et al., 2013a; Ying et al., 2012). In addition, because
immune rejection, tumorigenesis or ethical problems may be
resolved by the use of autologous cells, hASC may be applied for PD
treatment as a potential source for cellular therapy.
In this study, the potential application of hASC for PD treatment
was veriﬁed using the intravenous transplantation of hASC in the
6-OHDA-induced PD mouse model. Injected hASC improved motor
performance in the PDmouse model. The intravenous implantation
of hASC could be a more convenient approach for the recovery of
damage than direct implantation into the brain. Therefore, this
method can be a useful therapeutic strategy for PD and other
neurodegenerative diseases.
6-OHDA-induced mouse model among several neurotoxin
models was used for this study. This 6-OHDAmodel has amerit that
displays the hallmarks of PD. Though this model shows the disease
at end stage, it may be appropriate in the research of stem cell
therapy replacing cells for neuronal loss which proceeds according
to aging. Oxidative stress caused by 6-OHDA led to dopaminergic
neuronal cell death and mitochondrial dysfunction. Many studies
have reported that the structural and functional modiﬁcations of
cytosolic mitochondria were related to various neurodegenerative
diseases (Dexter et al., 1989; Moon et al., 2013; Shim et al., 2011;
Sriram et al., 1997). For that reason, this study preferentially
evaluated the effect of hASC on mitochondrial dysfunction.
Previous studies suggest that the effectiveness of hASC
transplantation might be attributed to their immunomodulatory,
H.S. Choi et al. / Neurobiology of Aging 36 (2015) 2885e2892 2891anti-inﬂammatory, and neurotrophic effects. In PD mice, the
transplantation of hASC exerted beneﬁcial pathological effects
including the recovery of dopaminergic neurons and the restoration
of cytosolic mitochondria.
PET imaging with raclopride, a dopamine D2 receptor
antagonist, showed an increased striatal dopamine level in
hASC- transplanted PD mice. We conﬁrmed the recovery
of dopaminergic neurons in the SN by assessing the immunostained
dopaminergic neurons with an anti-TH antibody. These
results showed decreased dopaminergic neuronal cell death in
hASC-injected PD mouse brains. The restored dopaminergic cell
death could be explained by recovering the mitochondrial
dysfunction. In the hASC-transplanted PD mouse brains, the
undamaged mitochondrial population was increased. Interestingly,
we also found an increased level of mitochondrial complex I
activity, which provides molecular evidence for the recovery of
mitochondrial function. Based on these results, treatment with
hASC may be expected to alleviate the symptoms of the disease or
slow the progression.
However, because there are many controversies about whether
hASC differentiate into neurons or mesenchymal tissue supporting
neurons, more research concerning themechanisms involved in the
neuronal differentiation will be necessary. Moreover, the speciﬁc
marker for hASC isolation from the stromal vascular fraction should
be developed for the preparation of hASC as therapeutic cell source
for PD. If the therapeutic potential of hASC is veriﬁed through these
further studies, it is expected to contribute to the breakthrough in
the treatment of PD.
As the elderly population increases, the incidence of neurode-
generative diseases and socioeconomic cost to treat it are
increasing. This study could suggest a potential possibility to
develop one of the candidates for the treatment of neurodegener-
ative diseases including PD.Disclosure statement
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